Kevin Carlton

Title: Kevin Carlton: Innovator in HIV-1 Research

Introduction

Kevin Carlton is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of HIV-1 research, holding two patents that focus on neutralizing antibodies. His work aims to advance the understanding and treatment of HIV-1 infections.

Latest Patents

Kevin Carlton's latest patents include "10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use." This patent discloses neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies. It also provides nucleic acids encoding these antibodies, vectors, and host cells. Methods for detecting HIV-1 using these antibodies are included, along with the use of these antibodies, antigen binding fragments, nucleic acids, and vectors to prevent and/or treat an HIV-1 infection. Another patent, "Neutralizing antibodies to HIV-1 GP41 and their use," shares similar findings and applications, emphasizing the importance of these antibodies in combating HIV-1.

Career Highlights

Throughout his career, Kevin Carlton has worked with esteemed organizations, including the Government of the United States of America as represented by the Secretary of the Department of Health and Human Services and Columbia University. His work has been pivotal in advancing research and therapeutic strategies against HIV-1.

Collaborations

Kevin has collaborated with notable colleagues such as Young Do Kwon and Ivelin Georgiev, contributing to the collective effort in HIV-1 research and innovation.

Conclusion

Kevin Carlton's innovative work in the field of HIV-1 research highlights his commitment to developing effective treatments and detection methods. His patents reflect significant advancements that could potentially change the landscape of HIV-1 therapy.